For CEO Kevin Gorman, the approval will be a vindication of many years work: he founded the company back in 1992, and suffered numerous setbacks along the way. Now Neurocrine Bioscience ...

Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...

Neurocrine Biosciences has a fifty-two week low of $105.18 and a fifty-two week high of $157.98. The firm has a market capitalization of $10.87 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.77 ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at ...

For the year to December 2024, Neurocrine Biosciences had an accrual ratio of -0.15. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer coverage changes suggests gradually increasing ...

In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” In case you ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...